Risdiplam (Evrysdi)

Small molecule

Also known as RO7034067

Approvedregulatory verdict

Evidence outlook

Approved: Spinal Muscular Atrophy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (2)
JP
  • Treatment of spinal muscular atrophy
Product first approved 2021PMDA
EU
  • Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Phase 2 (6)
Spinal Muscular Atrophy
NCT07047144 · Scholar Rock, Inc.
2025-09-15 – 2029-03 · Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
What this study did
NCT05808764 · Hoffmann-La Roche
2024-04-26 – 2026-05-04 · Muscular Atrophy, Spinal
What this study did
NCT03032172 · Hoffmann-La Roche
2017-03-03 – 2025-02-07 · Spinal Muscular Atrophy
What this study did
Phase 1 (6)
Spinal Muscular Atrophy
NCT03988907 · Hoffmann-La Roche
2019-06-18 – 2019-09-29 · Spinal Muscular Atrophy
What this study did
NCT02633709 · Hoffmann-La Roche
2016-01-07 – 2016-08-04 · Spinal Muscular Atrophy
What this study did
Other / comorbidity
NCT04718181 · Hoffmann-La Roche
2021-02-01 – 2023-01-28 · Muscular Atrophy, Spinal
What this study did
NCT03040635 · Hoffmann-La Roche
2017-03-22 – 2017-10-02 · Healthy Volunteers
What this study did
Phase 4 (4)
Spinal Muscular Atrophy
NCT05861986 · Hoffmann-La Roche
2024-05-30 – 2029-03-31 · Muscular Atrophy, Spinal
What this study did
NCT05232929 · Genentech, Inc.
2022-03-29 – 2026-10-09 · Spinal Muscular Atrophy
What this study did
NCT05522361 · Clinic for Special Children
2022-11-06 – 2026-06-15 · Spinal Muscular Atrophy
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Spinal Muscular Atrophy
NCT05115110 · Hoffmann-La Roche
2022-06-02 – 2026-11-02 · Spinal Muscular Atrophy (SMA)
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Spinal Muscular Atrophy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risdiplam (Evrysdi): this drugApprovedSmall moleculeSMN2 pre-mRNAnot yet gradedNo reviewed efficacy summary in this indication
Apitegromab (Isembyld)ApprovedMonoclonal antibodyMyostatin (pro/latent form)not yet gradedNo reviewed efficacy summary in this indication
Nusinersen (Spinraza)ApprovedRNA / oligonucleotideSMN2 pre-mRNAWeak signal
NCT02292537: Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9)
NCT01839656: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination): Nusinersen 6 mg 25 Percent of participants | Nusinersen 12 mg 68.8 Percent of participants
Taldefgrobep AlfaPhase 3Antibody-derived scaffoldActivin/myostatin type II receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Risdiplam (Evrysdi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (4)
March 2028 (2)
Phase 4Spinal Muscular AtrophyActive not recruiting
Est. primary completion 2028-03-31 · NCT05861999 · CT.gov ↗
What to watch
Phase 4Spinal Muscular AtrophyActive not recruiting
Est. primary completion 2028-03-31 · NCT05861986 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Spinal Muscular AtrophyRecruiting
Est. primary completion 2028-06-23 · NCT07444476 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Spinal Muscular AtrophyRecruiting
Est. primary completion 2028-11 · NCT07047144 · CT.gov ↗
What to watch

See the full readout calendar ↗